Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy
Authors' conclusion
93.1% of people currently on anti-hyperglycaemic treatment are now recommended or considered for SGLT2-inhibitor therapy under the new guidance, with the majority (59.6%) eligible on the basis of QRISK2 rather than established ASCVD or heart failure (33.6%).
Study context
- Population
- People with T2D currently on anti-hyperglycaemic treatment, contemporary population-representative UK cohort; NICE guidance: offer SGLT2i for established atherosclerotic cardiovascular disease (ASCVD) or HF, consider for 10-year CVD risk >10% (QRISK2)
- Outcome
- Proportion recommended or considered for SGLT2i therapy under the new NICE guidance
Methodological detailspopulation-representative UK cohort
- Population-representative UK cohort
Main finding
As reported in the abstract
Recommended or considered for SGLT2i therapy under new guidance
Recommended or considered for SGLT2i (people on anti-hyperglycaemic treatment)
93.1%
Eligible on basis of QRISK2
59.6%
Eligible on basis of established ASCVD or HF
33.6%
Observational data: associations, not effects.
Further findings
Projection to England
- People in England on anti-hyperglycaemic medication
- ≈2.20 million
- People now considered for additional SGLT2i therapy
- 1.75 million
- Total cost of SGLT2i therapy in England
- over £1 billion per year
Original publication
Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy. Cardiovasc Diabetol. Published 2 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →